Tilray | TRLY - Ebitda

Aktienkurs
9.23
Täglich Wechseln
-0.23 -2.43%
Monatlich
-3.75%
Jährlich
1,237.68%
Q2 Prognose
9.04




Ebitda Veränderung Datum
Acasti Pharma USD -2.45M 735K 2025-12
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Alaunos Therapeutics USD -21.02M 1.33M 2021-03
Aurora Cannabis CAD 18.48M 3.11M 2025-12
Avita Medical AUD -9.69M 12.21M 2025-12
Canopy Growth CAD -2.87M 19.49M 2025-12
Cronos Group USD 456K 5.22M 2025-12
Dianthus Therapeutics USD -40.19M 5.36M 2025-09
Divis Laboratories Ltd INR 8.9B 20M 2025-12
Ionis Pharmaceuticals USD -157.12M 307.36M 2025-09
IQVIA Holdings USD 1.05B 97M 2025-12
Knight Therapeutics CAD 24.45M 3.46M 2025-12
Moderna USD -790M 582M 2025-12
Organigram Holdings CAD 5.26M 884K 2025-12
Organon & Co USD 383M 135M 2025-12
Revvity USD 248.91M 48.52M 2025-12
Tectonic Therapeutic USD -21.18M 365K 2025-12
Tilray USD 8.36M 1.82M 2025-09
Viatris USD 1B 151.5M 2025-12
Xeris Pharmaceuticals USD 25.09M 7.67M 2025-12
Zealand Pharma A/S -727.47M 285.54M 2025-12